Antiviral activity of Isatis indigotica root-derived clemastanin B against human and avian influenza A and B viruses in vitro

Yang,Zifeng; Wang,Yutao; Zheng,Zhaoguang; Zhao,Suishan; Zhao,Jin; Lin,Qing; Li,Chuyuan; Zhu,Quan; Zhong,Nanshan

doi:10.3892/ijmm.2013.1274

Antiviral activity of Isatis indigotica root-derived clemastanin B against human and avian influenza A and B viruses in vitro

Authors:
- Zifeng Yang
- Yutao Wang
- Zhaoguang Zheng
- Suishan Zhao
- Jin Zhao
- Qing Lin
- Chuyuan Li
- Quan Zhu
- Nanshan Zhong
View Affiliations

Affiliations: Macau University of Science and Technology, Taipa, Macau, SAR, P.R. China, Clinical Virology Division, State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, P.R. China, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Guangzhou, P.R. China
Published online on: February 7, 2013 https://doi.org/10.3892/ijmm.2013.1274
Pages: 867-873

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clemastanin B, 7S,8R,8'R-(-)-lariciresinol-4,4'-bis-O-β-D-glucopyranoside, is one of the major lignans extracted from Isatis indigotica root (IIR). In this study, the anti-influenza activities of clemastanin B were evaluated in vitro. Clemastanin B was found to inhibit different subtypes of human (H1N1, including swine-origin H1N1; H3N2 and influenza B) and avian influenza viruses (H6N2, H7N3, H9N2) at different magnitudes of activity (IC50 0.087-0.72 mg/ml) while this compound was inactive against respiratory syncytial virus (RSV), adenovirus 3 (ADV3), parainfluenza virus 3 (PIV3), enterovirus 71 (EV71) and human rhinovirus (HRV). An apparent virus titer reduction was detected when MDCK cells were treated with clemastanin B after viral infection, particularly at the early stage, and the ribonucleoprotein (RNP) of the influenza virus was retained in the nucleus after treatment with clemastanin B. These results demonstrated that clemastanin B targets viral endocytosis, uncoating or RNP export from the nucleus. Furthermore, treatment with clemastanin B did not easily result in the emergence of viral drug resistance. The effects of clemastanin B demonstrated in this study may promote the antiviral study of IIR, but additional studies are required to define the anti-influenza mechanism(s).

View Figures

View References

1	Nicholson KG, Wood JM and Zambon M: Influenza. Lancet. 362:1733–1745. 2003. View Article : Google Scholar : PubMed/NCBI
2	Trifonov V, Khiabanian H, Greenbaum B and Rabadan R: The origin of the recent swine influenza seasonal influenza A(H1N1) virus infecting humans. Euro Surveill. 14:191932009.PubMed/NCBI
3	Centers for Disease Control and Prevention (CDC). Update: Infections with a Swine-Origin Influenza A (H1N1) Virus, United States and other countries. 2009, http://www.cdc.gov/mmwr.
4	Hayden FG and Hay AJ: Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol. 176:119–130. 1992.PubMed/NCBI
5	de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH and Farrar J: Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 353:2667–2672. 2005.
6	Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, Shu Y, Gubareva LV, Cox NJ and Klimov AI: Surveillance of resistance to adamantanes among influenza A (H3N2) and A (H1N1) viruses isolated worldwide. J Infect Dis. 196:249–257. 2007. View Article : Google Scholar : PubMed/NCBI
7	Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y and Kawaoka Y: Avian flu: isolation of drug-resistant H5N1 virus. Nature. 437:11082005. View Article : Google Scholar : PubMed/NCBI
8	Shetty AK and Peek LA: Peramivir for the treatment of influenza. Expert Rev Anti Infect Ther. 10:123–143. 2012. View Article : Google Scholar : PubMed/NCBI
9	Chang YS and Ho YL: Studies on the homonymic Chinese crude drug species in Taiwan. Evaluation of the quality of DA-Ching-Yeh and Ching-Dai. Anal Sci. 17:a423–a426. 2001.
10	Xu LH, Huang F, Cheng T and Wu J: Antivirus constituents of radix of Isatis indigotica. Chin J Nat Med. 3:359–361. 2005.
11	Li L, Dong TY, Li XL and Qiao CZ: Study of quality control on herbal drugs and preparations of daqingye and banlangen. Acta Pharm Sin. 28:229–233. 1993.(In Chinese).
12	Huang QS, Yoshihiro K and Natori S: Isolation of 2-hydroxy -3-butenyl thiocyanate, epigoitrin and adenosine from ‘banlangen’, Isatis indigotica root. Planta Med. 42:308–310. 1981.PubMed/NCBI
13	Li X, He LW and Sun DD: The methods of anti-virus extract from Radix and its use. P: CN1969923. pp. 05–30. 2007
14	Zuo Y, Dai M, Wang ZY and Liu J: Effects of banlangen polysaccharide on mice resistance to Influenza virus infection. WCJ PS. 23:666–667. 2008.
15	An YQ, Jia XB, Yuan HJ, Chen Y and Jin XY: Thinking in studies on antiviral material base of Radix isatidis. Chin Tradit Herbal Drugs. 39:616–619. 2008.
16	Kizu H, Shimana H and Tomimori T: Studies on the constituents of clematis species. VI The Constituents of Clematis stans Sieb et Zucc. Chem Pharm Bull. 43:2187–2194. 1995. View Article : Google Scholar : PubMed/NCBI
17	He LW, LI X, Chen JW, Xia Y and Wang YY: Determination of lariciresinol-4,4′-bis-O-b-D-glucopyranoside from Radix isatidis by HPLC. Chin Tradit Herbal Drugs. 39:1895–1897. 2008.
18	Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, Poetter A, Dreschers S, Schmolke M, Planz O and Ludwig S: A polyphenol rich plant extract, CYSTUS052, exerts anti-influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral Res. 76:38–47. 2007. View Article : Google Scholar : PubMed/NCBI
19	Yingsakmongkon S, Miyamoto D, Sriwilaijaroen N, Fujita K, Matsumoto K, Jampangern W, Hiramatsu H, Guo CT, Sawada T, Takahashi T, Hidari K, Suzuki T, Ito M, Ito Y and Suzuki Y: In vitro inhibition of human influenza A virus infection by fruit-juice concentrate of Japanese plum (Prunus mume SIEB. et ZUCC). Biol Pharm Bull. 31:511–515. 2008. View Article : Google Scholar : PubMed/NCBI
20	Miyamoto D, Hasegawa S, Sriwilaijaroen N, Yingsakmongkon S, Hiramatsu H, Takahashi T, Hidari K, Guo CT, Sakano Y, Suzuki T and Suzuki Y: Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. Biol Pharm Bull. 31:217–222. 2008. View Article : Google Scholar : PubMed/NCBI
21	Knox YM, Suzutani T, Yosida I and Azuma M: Anti-influenza virus activity of crude extract of Ribes nigrum L. Phytother Res. 17:120–122. 2003. View Article : Google Scholar : PubMed/NCBI
22	Graham BS, Perkins MD, Wright PF and Karzon DT: Primary respiratory syncytial virus infection in mice. J Med Virol. 26:153–162. 1998. View Article : Google Scholar
23	Hui MB, Lien EJ and Trousdale MD: Inhibition of human adenoviruses by 1-(2′-hydroxy-5′-methoxybenzylidene) amino-3-hydroxyguanidine tosylate. Antiviral Res. 24:261–273. 1994.
24	Mao H, Thakur CS, Chattopadhyay S, Silverman RH, Gudkov A and Banerjee AK: Inhibition of human parainfluenza virus type 3 infection by novel small molecules. Antiviral Res. 77:83–94. 2008. View Article : Google Scholar : PubMed/NCBI
25	Ho HY, Cheng ML, Weng SF, Leu YL and Chiu DT: Antiviral effect of epigallocatechin gallate on enterovirus 71. J Agric Food Chem. 57:6140–6147. 2009. View Article : Google Scholar : PubMed/NCBI
26	Kaiser L, Crump CE and Hayden FG: In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res. 7:215–220. 2000. View Article : Google Scholar : PubMed/NCBI
27	Reed LJ and Muench H: A simple method of estimating fifty percent endpoints. Am J Hyg. 27:493–497. 1938.
28	Ludwig S, Wolff T, Ehrhardt C, Wurzer WJ, Reinhardt J, Planz O and Pleschka S: MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett. 561:37–43. 2004. View Article : Google Scholar : PubMed/NCBI
29	Peng JP, Fan GR and Wu YT: Isolation and purification of clemastanin B and indigoticoside A from Radix isatidis by high-speed counter-current chromatography. J Chromatogr A. 1091:89–93. 2005. View Article : Google Scholar : PubMed/NCBI
30	Taubenberger JK: The origin and virulence of the 1918 ‘Spanish’ influenza virus. Proc Am Philos Soc. 150:86–112. 2006.
31	Mak NK, Leung CY, Wei XY, Shen XL, Wong RN, Leung KN and Fung MC: Inhibition of RANTES expression by indirubin in influenza virus-infected human bronchial epithelial cells. Biochem Pharmacol. 67:167–174. 2004. View Article : Google Scholar : PubMed/NCBI
32	Yamada H: Antiviral compositions containing new glycoprotein from Isatis tinctoria. Acta Pharm Sin. 1160:5991999.
33	Palese P: Influenza: old and new threats. Nat Med. 10(Suppl 12): S82–S87. 2004. View Article : Google Scholar : PubMed/NCBI
34	Pleschka S, Wolff T, Ehrhardt C, Hobom G, Planz O, Rapp UR and Ludwig S: Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol. 3:301–305. 2001. View Article : Google Scholar : PubMed/NCBI
35	Marjuki H, Alam MI, Ehrhardt C, Wagner R, Planz O, Klenk HD, Ludwig S and Pleschka S: Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling. J Biol Chem. 81:16707–16715. 2006. View Article : Google Scholar
36	Wu MS, Yen HR, Chang CW, Peng TY, Hsieh CF, Chen CJ, Lin TY and Horng JT: Mechanism of action of the suppression of influenza virus replication by Ko-Ken Tang through inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway and viral RNP nuclear export. J Ethnopharmacol. 134:614–623. 2011. View Article : Google Scholar : PubMed/NCBI
37	Mazur I, Wurzer WJ, Ehrhardt C, Pleschka S, Puthavathana P, Silberzahn T, Wolff T, Planz O and Ludwig S: Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol. 9:1683–1694. 2007. View Article : Google Scholar : PubMed/NCBI
38	Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ and Klimov AI: Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 366:1175–1181. 2005. View Article : Google Scholar : PubMed/NCBI
39	Bright RA, Shay DK, Shu B, Cox NJ and Klimov AI: Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA. 295:891–894. 2006.
40	Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB and Uyeki TM: Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 360:2605–2615. 2009. View Article : Google Scholar : PubMed/NCBI